TVRD · Tvardi Therapeutics, Inc.
$1.82
+0.02 (+1.11%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that its present capital resources as of June 30, 2026 will not be sufficient to fund its planned operations for at least one year from the issuance date of the unaudited condensed consolidated financial statements, included elsewhere in this Quarterly Report, which raises substantial doubt as to our ability to continue as a going concern. We plan to seek additional funding through equity offerings, including through our ATM Facility, or debt financings, credit or loan facilities, strategic alliances and licensing arrangements. However, there can be no assurance that such funding will be available to us, will be obtained on terms favorable to us, or will provide us with sufficient funds to meet our objectives.”View the 10-Q filed Aug 14, 2026
Market Cap
$24.28M
Shares
13.34M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-07-07 | Topline Results from Phase 1 Healthy Volunteer Study of TTI-109 | Event |
| 2026-06-04 | Jefferies Global Healthcare Conference | Conference |
| 2026-03-10 | Barclays 28th Annual Global Healthcare Conference | Conference |
| 2026-03-03 | TD Cowen 46th Annual Health Care Conference | Conference |
| 2026-02-25 | Oppenheimer 36th Annual Healthcare Life Sciences Conference | Conference |
| 2026-02-19 | JonesTrading C-Suite Fireside Chat Series | Event |
Source: https://tvarditherapeutics.com/ir-navigation-header/
Key facts
CIK
1346830
CUSIP
140755307
13F (30d)
46 filings
46 filers
Visit website
Investor relations